SCA
BMY icon

Spearhead Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Spearhead Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,757
Closed -$305K – 109
2019
Q4 		$305K Hold
4,757
– – 0.08% 76
2019
Q3 		$241K Hold
4,757
– – 0.07% 80
2019
Q2 		$216K Buy
+4,757
New +$222K 0.06% 84

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spearhead Capital Advisors's BMY Position: Q1 2020 in Review

Spearhead Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2020, closing a stake of 4,757 shares — an estimated $305K sold.

Spearhead Capital Advisors first reported a position in BMY in Q2 2019 and held it in 3 quarters. The position peaked at $305K in Q4 2019. 2,148 funds tracked by Wall St. Rank hold BMY as of Q1 2020.

  • Spearhead Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2020 after selling out during the quarter.
  • Spearhead Capital Advisors sold 4,757 Bristol-Myers Squibb shares in Q1 2020, an estimated $305K.
  • Spearhead Capital Advisors first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 3 quarters.
  • Spearhead Capital Advisors's Bristol-Myers Squibb position peaked at $305K in Q4 2019.
  • 2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2020.

Based on Spearhead Capital Advisors's 13F filing for Q1 2020, filed 17 Apr 2020.